ஜான் சூங் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Senhwa concludes enrolment in Phase II oral Covid-19 drug trial

Senhwa concludes enrolment in Phase II oral Covid-19 drug trial
clinicaltrialsarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicaltrialsarena.com Daily Mail and Mail on Sunday newspapers.

John soongSenhwa biosciencesTai sen soongTaiwan centerIndia central drugs standard control organizationRegulatory consultation programDrug evaluationConsultation programSen soongCentral drugs standard control organizationஜான் சூங்தை சென் சூங்டைவாந் மையம்இந்தியா மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்மருந்து மதிப்பீடுமைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்

Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19

/PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focused on human efficacy and innovation of first-in-class therapeutics.

T ai peiUnited statesSan diegoJohn soongSenhwa biosciencesSenhwa bioscienceTai sen soongSenhwa biosciences incUs centers for diseasePrnewswire senhwa biosciences incChief executive officerDisease controlChief medical officerOrphan drug designationRare pediatric disease drug designationMedical pharmaceuticals

Data Demonstrate Efficacy of Silmitasertib Plus Gemcitabine and Cisplatin Combination Treatment for Cholangiocarcinoma

Data Demonstrate Efficacy of Silmitasertib Plus Gemcitabine and Cisplatin Combination Treatment for Cholangiocarcinoma
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.

United statesJohn soongSenhwa biosciencesAmerican societyஒன்றுபட்டது மாநிலங்களில்ஜான் சூங்அமெரிக்கன் சமூகம்

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19

Share this article Share this article TAIPEI and SAN DIEGO, Jan. 21, 2021 /PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient has enrolled into an investigator-initiated trial (IIT) of its investigational drug, Silmitasertib, as a treatment for hospitalized COVID-19 patients at Banner Health-University Medical Center in Phoenix, Arizona (BUMCP). This IIT is a Phase II multi-center, open-label, randomized, controlled interventional prospective study. BUMCP intends to enroll 40 patients with severe COVID-19, where half will receive Silmitasertib for 14 days. Senhwa s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. It is thought that Silmitasertib challenges the virus

United statesT ai peiSan diegoUniversity medical centerJohn soongGlassberg cseteSenhwa biosciencesMarilyn glassberg cseteSenhwa silmitasertibChris recknorEsa rayyanSenhwa biosciences incBanner healthPrnewswire senhwa biosciences incBanner health university medical centerPrinciple investigator

Senhwa Biosciences Receives US FDA Study May Proceed Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461

Share: TAIPEI and SAN DIEGO, Dec. 23. 2020 /PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a Study May Proceed letter from the US Food and Drug Administration (FDA) to begin a Phase Ib study evaluating CX-5461, a first-in-class G-quadruplex stabilizer, to treat solid tumors with BRCA2 or PALB2 mutations. The FDA s approval of our Phase Ib clinical trial application for testing CX-5461 in patients with BRCA2 or PALB2 mutations is an important milestone and marks a new paradigm in the treatment of cancers with specific pathogenic mutations, stated Dr. John Soong, the Chief Medical Officer of Senhwa Biosciences.

T ai peiUnited statesSan diegoJohn soongSenhwa biosciencesSenhwa bioscienceTai sen soongCanadian cancer trial groupDrug administrationPrnewswire senhwa biosciences incSenhwa biosciences incCancer dream team grantProstate cancer foundationHealth canadaChief medical officerDream team grant